- Home
- GLRE vs ABVX Comparison
GLRE vs ABVX Comparison
Compare GLRE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- ABVX
- Stock Information
- Founded
- GLRE 2004
- ABVX 2013
- Country
- GLRE Cayman Islands
- ABVX France
- Employees
- GLRE N/A
- ABVX N/A
- Industry
- GLRE Property-Casualty Insurers
- ABVX
- Sector
- GLRE Finance
- ABVX
- Exchange
- GLRE Nasdaq
- ABVX Nasdaq
- Market Cap
- GLRE 466.5M
- ABVX 511.3M
- IPO Year
- GLRE 2007
- ABVX N/A
- Fundamental
- Price
- GLRE $14.40
- ABVX $5.97
- Analyst Decision
- GLRE
- ABVX Buy
- Analyst Count
- GLRE 0
- ABVX 4
- Target Price
- GLRE N/A
- ABVX $31.50
- AVG Volume (30 Days)
- GLRE 112.1K
- ABVX 320.0K
- Earning Date
- GLRE 08-05-2025
- ABVX 03-24-2025
- Dividend Yield
- GLRE N/A
- ABVX N/A
- EPS Growth
- GLRE N/A
- ABVX N/A
- EPS
- GLRE 1.32
- ABVX N/A
- Revenue
- GLRE $717,617,000.00
- ABVX $11,444,012.00
- Revenue This Year
- GLRE N/A
- ABVX $284.20
- Revenue Next Year
- GLRE N/A
- ABVX N/A
- P/E Ratio
- GLRE $10.94
- ABVX N/A
- Revenue Growth
- GLRE 2.79
- ABVX 128.98
- 52 Week Low
- GLRE $11.95
- ABVX $4.77
- 52 Week High
- GLRE $15.82
- ABVX $14.22
- Technical
- Relative Strength Index (RSI)
- GLRE 55.37
- ABVX 38.44
- Support Level
- GLRE $14.35
- ABVX $5.75
- Resistance Level
- GLRE $15.07
- ABVX $8.57
- Average True Range (ATR)
- GLRE 0.29
- ABVX 0.55
- MACD
- GLRE -0.04
- ABVX -0.17
- Stochastic Oscillator
- GLRE 37.38
- ABVX 7.69
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.